"The release of public data is the next big world in the clinical trials space and neutral third parties who are not part of the trial are going to innovate using our trials data." Atul Butte MD, PhD, Director of the Institute of Computational Health Sciences, University of California, San Francisco (UCSF)
The release of public data is the future of clinical trials. With about 50% of clinical trials failing, outside of summaries on clinicaltrials.gov, the raw data is never distributed for review. And what would this mean for the industry? It means that more questioning and review would happen, truly getting to the bottom of why a trial failed or succeeded. These third party researchers will be able to draw conclusions, like for instance "that the drug is working in a subset of patients", then that discovery will be present in trials moving forward - thus innovating the field.
Find out all the good that Atul feels proper data management and review will have for the industry in this exclusive interview.